Medicare to Cover Wegovy and Zepbound at $50/Month Starting July 1

Medicare will cover select GLP-1 weight-loss medications for the first time starting July 1, 2026.

Medicare Opens the Door to Weight-Loss Medication Coverage

For the first time in the program's history, Medicare beneficiaries will have access to FDA-approved weight-loss medications at an affordable price. According to the Centers for Medicare & Medicaid Services (CMS), the Medicare GLP-1 Bridge program is set to launch on July 1, 2026, providing eligible Part D enrollees with access to select GLP-1 receptor agonist medications for a $50 monthly copay per 30-day supply.

The program, which CMS describes as a temporary nationwide demonstration, is scheduled to run through December 31, 2027. It represents a significant policy shift, as Medicare has historically been prohibited by statute from covering medications prescribed solely for weight management, according to the Kaiser Family Foundation (KFF).

Which Medications Are Covered

According to CMS guidance, the GLP-1 Bridge program covers the following FDA-approved medications:

• Wegovy (semaglutide) — all formulations, including injection and tablet
• Zepbound (tirzepatide) — KwikPen formulation only (single-dose vial and single-dose pen are not included)
• Foundayo — all formulations

Beneficiaries who are already receiving a GLP-1 medication through their standard Part D plan for conditions such as type 2 diabetes will continue to access those prescriptions through their existing coverage, CMS noted. Those interested in learning more about semaglutide treatment programs or tirzepatide options may want to discuss eligibility with their healthcare provider.

Who Qualifies for the Program

The GLP-1 Bridge program is not automatically available to all Medicare enrollees. According to CMS, beneficiaries must meet specific clinical and enrollment criteria to participate:

• Active enrollment in a Medicare Part D plan or a Medicare Advantage plan with prescription drug coverage (MA-PD)
• A BMI of 35 or greater, with no additional conditions required
• A BMI of 30 or greater with a diagnosis of heart failure, uncontrolled hypertension, or chronic kidney disease
• A BMI of 27 or greater with prediabetes, a previous heart attack, previous stroke, or symptomatic peripheral artery disease

Healthcare providers must submit a prescription and prior authorization request through a CMS central processor to confirm eligibility. According to CMS, the electronic submission process is expected to be available starting July 1, 2026, with additional details being released in June.

Key Details and Limitations

KFF analysis notes several important limitations that beneficiaries should be aware of. Because the Bridge program operates outside the standard Part D benefit structure, the $50 copayments do not count toward a beneficiary's Part D deductible or annual out-of-pocket spending cap. Additionally, manufacturer coupons or discount cards cannot be applied to further reduce the copay.

The program potentially affects more than 67 million Medicare beneficiaries nationwide, according to CMS estimates, though the actual number of participants will depend on how many meet the clinical criteria and complete the prior authorization process.

What Comes Next

The Obesity Action Coalition and other advocacy groups have noted that the Bridge program fills a critical gap in care while longer-term policy solutions are being developed. CMS had previously announced a more comprehensive initiative called the BALANCE Model, but according to KFF, its implementation has been indefinitely delayed.

Beneficiaries who believe they may qualify are encouraged to speak with their healthcare provider about the clinical requirements and the prior authorization process. To check if you qualify for weight-management medication programs, consult with a licensed provider who can review your medical history and BMI.

This article is for informational purposes only and is not medical advice. Consult your healthcare provider before starting any weight loss medication or treatment.